Summary
Background. Tamoxifen has been shown to reduce the incidence of invasive breast cancer in women at higher risk. Translating these research results to clinical practice is challenging. Our objective was to develop and evaluate a decision-making guide and process that can be used in clinical practice to inform eligible women of chemoprevention with tamoxifen.
Methods. A decision guide explaining the benefits and risks of tamoxifen was developed with input from health care professionals and two focus groups of women both with and without cancer. Following consent, 51 eligible women presenting to a multi-disciplinary diagnostic facility for breast problems were given the decision guide/questionnaire to read, fill out and return by mail. Women with further questions or wanting to take tamoxifen were encouraged to re-contact their physicians.
Results. Atypia was seen in 60% of subjects. Median 5-year Gail risk was 3.7 (range 1.7–9.4). Only 6 (11.8% 95% CI = 2.9, 20.6%) women reported they would like to take tamoxifen while 6 (11.8% 95% CI = 2.9, 20.6%) remained uncertain.
Conclusion. We have developed a decision-making guide and process that is acceptable to providers and women to identify and inform women at higher risk of breast cancer with regard to chemoprevention with tamoxifen. Few women in this select group, when provided with a balanced decision guide, wished to pursue chemoprevention with tamoxifesn
Similar content being viewed by others
References
B Fisher JP Costantino DL Wickerham CK Redmond M Kavanah WM Cronin V Vogel A Robidoux N Dimitrov J Atkins M Daly S Wieand E Tan-Chiu L Ford N Wolmark (1998) ArticleTitleTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371–1388 Occurrence Handle10.1093/jnci/90.18.1371 Occurrence Handle9747868
M Levine JM Moutquin R Walton J Feightner (2001) ArticleTitleChemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative’s Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer CMAJ 164 1681–1690 Occurrence Handle11450210
U.S. Preventative Services Task Force: Chemoprevention of Breast Cancer. http://www ahrq gov/clinic/3rduspstf/breastchemo/ 1–7–2002
B Fisher (2000) ArticleTitleRe: tamoxifen prevention of breast cancer: an instance of the fingerpost J Natl Cancer Inst 92 659–660 Occurrence Handle10.1093/jnci/92.8.659 Occurrence Handle10772691
AM O’Connor (1989) ArticleTitleEffects of framing and level of probability on patients’ preferences for cancer chemotherapy J Clin Epidemiol 42 119–126 Occurrence Handle10.1016/0895-4356(89)90085-1 Occurrence Handle2918321
ML Slevin L Stubbs HJ Plant P Wilson WM Gregory PJ Armes SM Downer (1990) ArticleTitleAttitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public BMJ 300 1458–1460 Occurrence Handle2379006
ER Port LL Montgomery AS Heerdt PI Borgen (2001) ArticleTitlePatient reluctance toward tamoxifen use for breast cancer primary prevention Ann Surg Oncol 8 580–585 Occurrence Handle11508619
J Tchou N Hou A Rademaker VC Jordan M Morrow (2004) ArticleTitleAcceptance of tamoxifen chemoprevention by physicians and women at risk Cancer 100 1800–1806 Occurrence Handle10.1002/cncr.20205 Occurrence Handle15112259
MH Gail LA Brinton DP Byar DK Corle SB Green C Schairer JJ Mulvihill (1989) ArticleTitleProjecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1879–1886 Occurrence Handle2593165
S Woloshin LM Schwartz S Byram B Fischhoff HG Welch (2000) ArticleTitleA new scale for assessing perceptions of chance: a validation study Med Decis Making 20 298–307 Occurrence Handle10929852
BK Rimer JM Schildkraut C Lerman TH Lin J Audrain (1996) ArticleTitleParticipation in a women’s breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium Cancer 77 2348–2355 Occurrence Handle10.1002/(SICI)1097-0142(19960601)77:11<2348::AID-CNCR25>3.0.CO;2-W Occurrence Handle8635106
C Lerman B Trock BK Rimer A Boyce C Jepson PF Engstrom (1991) ArticleTitlePsychological and behavioral implications of abnormal mammograms Ann Intern Med 114 657–661 Occurrence Handle2003712
DA Dillman (1978) Mail and Telephone Surveys: The Total Design Method Wiley New York
D Stacey AM O’Connor C DeGrasse S Verma (2003) ArticleTitleDevelopment and evaluation of a breast cancer prevention decision aid for higher-risk women Health Expect 6 3–18 Occurrence Handle10.1046/j.1369-6513.2003.00195.x Occurrence Handle12603624
C Zimmermann C Baldo A Molino (2000) ArticleTitleFraming of outcome and probability of recurrence: breast cancer patients’ choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios Breast Cancer Res Treat 60 9–14 Occurrence Handle10.1023/A:1006342316373 Occurrence Handle10845804
MN Levine A Gafni B Markham D MacFarlane (1992) ArticleTitleA bedside decision instrument to elicit a patient’s preference concerning adjuvant chemotherapy for breast cancer Ann Intern Med 117 53–58 Occurrence Handle1596048
RP McQuellon HB Muss SL Hoffman G Russell B Craven SB Yellen (1995) ArticleTitlePatient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer J Clin Oncol 13 858–868 Occurrence Handle7707112
AM O’Connor NF Boyd P Warde L Stolbach JE Till (1987) ArticleTitleEliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences J Chronic Dis 40 811–818 Occurrence Handle10.1016/0021-9681(87)90133-0 Occurrence Handle3597681
SB Yellen DF Cella WT Leslie (1994) ArticleTitleAge and clinical decision making in oncology patients J Natl Cancer Inst 86 1766–1770 Occurrence Handle7966414
A Veronesi MA Pizzichetta MA Ferlante M Zottar MD Magri D Crivellari S Foladore (1998) ArticleTitleTamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment Tumori 84 372–375 Occurrence Handle9678620
JA Tangrea (1997) ArticleTitlePatient participation and compliance in cancer chemoprevention trials: issues and concerns Proc Soc Exp Biol Med 216 260–265 Occurrence Handle9349695
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McKay, A., Martin, W. & Latosinsky, S. How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide. Breast Cancer Res Treat 94, 153–159 (2005). https://doi.org/10.1007/s10549-005-6932-6
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-6932-6